American Society of Hirudotherapy

Burning Mouth Syndrome (Investigational Adjunct)

Investigational adjunct for primary burning mouth syndrome; clonazepam (topical or systemic), alpha-lipoic acid, low-dose tricyclics, and cognitive behavioral therapy remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for burning mouth syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for burning mouth syndrome is investigational.
What evidence exists?
Tier C (investigational). The only clinical reports identified are small, uncontrolled or non-randomized studies from Russia (the largest, from 1987, described 25 patients); there are no randomized controlled trials. Evidence-based management: rule out secondary causes (candidiasis, oral lichen planus, dry mouth, nutritional deficiencies B12/iron/folate/zinc, denture issues, hormonal changes, medication side effects, neuropathy), then treat primary burning mouth syndrome with topical clonazepam, alpha-lipoic acid, low-dose tricyclic antidepressants, gabapentin, or cognitive-behavioral therapy. Most cases improve with multimodal approach over months.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening of oral burning sensation
  • Local skin infection or, rarely, Aeromonas infection if bites near mouth
  • Allergic reaction to leech saliva (uncommon)
  • Risk of leech placement intraorally is dangerous and not recommended
  • Trigger of new burning, stinging, or numbness
  • Delay of nutritional workup and treatment of secondary causes
  • Cosmetic disfigurement if bites placed on the face
Who should not consider this
  • Patients without a workup for secondary causes (B12, iron, folate, zinc, glucose, thyroid)
  • Patients with active oral candidiasis, lichen planus, or dry mouth
  • Patients with denture-related irritation (refit dentures first)
  • Patients with active dental or gingival infection
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients who have not tried topical clonazepam, alpha-lipoic acid, or tricyclic antidepressants
What to ask your clinician
  • Have I been worked up for nutritional deficiencies (B12, iron, folate, zinc)?
  • Has oral candidiasis or lichen planus been ruled out?
  • Have I tried topical clonazepam swish-and-spit?
  • Am I a candidate for alpha-lipoic acid or low-dose tricyclic antidepressants?
  • Have I been evaluated for medication-induced dry mouth or burning?
  • What evidence specifically supports leech therapy for burning mouth syndrome?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • New facial weakness, numbness, or slurred speech (possible stroke or neurologic)
  • New oral ulcers, white patches, or thickened plaques (possible candidiasis, lichen planus, or malignancy)
  • Severe dry mouth with eye dryness (possible Sjogren syndrome)
  • Difficulty swallowing or new hoarseness
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for burning mouth syndrome.
  • Small uncontrolled reports do NOT establish efficacy versus topical clonazepam, alpha-lipoic acid, or tricyclic antidepressants.
  • It does NOT replace workup for nutritional deficiencies and secondary causes.
  • It does NOT substitute for treatment of candidiasis, lichen planus, dry mouth, or Sjogren syndrome.
  • It does NOT mean intraoral leech application is appropriate — this is not a safe target.

Clinical Profile

Category
ENT
ICD-10
K14.6, K14.8, R20.8
Safety tier
High

Evidence Summary

Primary (idiopathic) burning mouth syndrome is a chronic neuropathic pain disorder of the oral mucosa with normal clinical examination, predominantly affecting peri- and postmenopausal women. Evidence-based options include topical or low-dose oral clonazepam, alpha-lipoic acid, low-dose amitriptyline or nortriptyline, gabapentinoids, and cognitive behavioral therapy. Secondary causes (candidiasis, xerostomia, nutritional deficiency, denture trauma, oral lichen planus, diabetes) must be excluded first. No randomized controlled trial of hirudotherapy for burning mouth syndrome was identified in PubMed, Europe PMC, ClinicalTrials.gov or the Baskova and Isakhanyan 2004 monograph. Small Russian clinical reports exist. Spitsyna (1987, PMID 3470985) treated 25 patients with stomatalgia (glossalgia) and reported that the burning resolved. Gileva and Kardynova (1997) compared 10 patients given leeches plus conventional treatment with 10 given conventional treatment alone and reported better taste-receptor function in the leech group. Neither report describes randomization, no control group is described for the 1987 series, and both are known mainly from the Baskova and Isakhanyan 2004 monograph (the PubMed record for the 1987 paper has no abstract). Intra-oral application is absolutely contraindicated.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • The term “burning mouth syndrome” does not appear in the book by Baskova and Isakhanyan; closest to it in description is glossalgia (also called stomalgia), which the authors list among the indications for hirudotherapy in dentistry and describe as a complex pain and paresthetic phenomenon (pain and unusual sensations) in the tongue and adjacent areas of the oral mucosa, often accompanied by a distorted sense of taste[B1].
  • Baskova and Isakhanyan write that in an observation by Spitsyna (1987) hirudotherapy was prescribed to 25 patients with stomalgia (glossalgia): according to the description, after treatment the burning of the tongue went away, the patients said that the tongue had “become thinner”, had become light, controllable, imperceptible, and the swelling and congestion in it disappeared; it is not clear from the text whether there was a comparison group, how long the patients were followed, and whether all of them had this result[B1].
  • Next, the book describes a comparison of two groups of 10 patients with glossalgia each (the definition of glossalgia precedes it, with a reference to Gileva and Kardynova, 1997): the control group received conventional treatment, the main group the same plus hirudotherapy; in the main group, on an empty stomach, a tendency toward improved function of the taste receptors was noted, in the control group a likewise positive but statistically nonsignificant trend; the authors of the book conclude that these data “convincingly show” a positive effect of hirudotherapy on the sense of taste in the combined management of glossalgia; whether burning or pain was assessed in these groups is not clear from the text[B1].
  • Michalsen et al. do not write about glossalgia, stomalgia or burning in the mouth.
  • In the chapter on indications and contraindications, Baskova and Isakhanyan name, among others, the following cases in which hirudotherapy is contraindicated: hemophilia, hemorrhagic diatheses, anemias, low blood pressure (hypotension), acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent prescription of anticoagulants (especially with long-term, daily use), concurrent use of alcohol, external use of large doses of mercury preparations together with leeches, individual intolerance, and an extremely negative attitude of the patient toward leeches[B1].
  • Michalsen et al. (chapter 8, Flecken and Michalsen) name hemophilia and concurrent use of anticoagulants as an absolute contraindication; in the same chapter, anemia and bone-marrow suppression, HIV infection, a known peptic ulcer or erosive gastritis, severe unstable disease of the internal organs or marked suppression of the immune system, a severe tendency to allergy, and emaciation of any cause are also listed as contraindications[B3].
  • Baskova and Isakhanyan consider hirudotherapy relatively contraindicated where leeches could lead to cosmetic defects, advise refraining from it when body temperature is high, and call its use in pregnancy an open question; Michalsen et al. write that treatment involving blood loss is generally contraindicated in pregnancy and that, in their experience, during the acute stage of an infectious disease it can cause weakness and impair wound healing[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Intra-oral placement (absolute)
  • Untreated secondary cause (candidiasis, anemia, B12/iron deficiency, diabetes)
  • Active oral lichen planus or stomatitis at placement region
  • Dental abscess or recent dental surgery

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.